Phantom股价暴跌12%;股价为1.3亿美元，每股16美元

2026-01-08 14:40

Phathom Pharmaceutical (PHAT) priced an underwritten public offering of ~6.88M shares and pre-funded warrants to purchase ~1.25M shares.
The shares of common stock are being sold to the public at a price of $16.00 per share and the pre-funded warrants are being sold at a price of $15.999 per pre-funded warrant.
The gross proceeds are expected to be ~$130M. The underwriters have a 30-day option to purchase an additional ~1.22M shares.
Net proceeds from the offering for general corporate purposes, including for working capital and commercialization and research and development expenses.
The offering is expected to close on or about January 9, 2026.
The stock price fell ~12% on Thursday during pre-market hours of trading.
More on Phathom Pharmaceuticals
- Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth
- Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript
- Phathom Pharma plans public offering after reporting preliminary 2025 results
- Phathom Pharmaceuticals reports Preliminary Q4 results
- Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals

More on Phathom Pharmaceuticals